Connecting to Global Pharmaceutical Ecosystem, Expanding International Peptide Business
— Hainan Zhonghe Pharmaceutical Shines at CPHI Milan 2026
2026年10月6日至8日，全球制药行业最具影响力的年度盛会——世界制药原料展览会（CPHI Worldwide 2026）在意大利米兰国际展览中心圆满举行。作为全球规模最大、覆盖产业链最全的制药专业展会，本届盛会汇聚了来自中国、美国、印度、意大利、日本等众多国家和地区的参展商及专业观众，是洞察行业趋势、链接全球资源的核心平台。
From October 6 to 8, 2026, CPHI Worldwide 2026, one of the most influential annual events in the global pharmaceutical industry, was successfully held at Fiera Milano, Italy. As the world’s largest pharmaceutical professional exhibition covering the most comprehensive industrial‑chain sectors, this grand event brought together exhibitors and professional visitors from China, the United States, India, Italy, Japan and many other countries and regions. It serves as a core platform for gaining insights into industry trends and connecting global resources.
作为中国化学合成多肽药物研发与生产的领军企业，海南中和药业股份有限公司（以下简称"海南中和药业"）携领先的多肽原料药及制剂产品线盛装出席。本次展会，公司多部门共同参与，形成"商务＋研发＋质量"的高效协同团队，与全球业界伙伴开展深度交流，充分展示了公司在多肽领域的生产实力与国际化战略布局。
As a leading Chinese enterprise engaged in the R&D and manufacturing of chemically‑synthesized peptide medicines, Hainan Zhonghe Pharmaceutical Co., Ltd. (hereinafter referred to as “Hainan Zhonghe Pharmaceutical”) showcased its advanced portfolio of peptide APIs and finished pharmaceutical products at the exhibition. A cross‑functional team integrating business, R&D and quality functions participated in the event. The team conducted in‑depth exchanges with industry partners worldwide, fully demonstrating the Company’s manufacturing strengths and international strategic layout in the peptide sector.
展会期间，我们与来自欧洲、中亚、东南亚、中东等多个国家和地区的客户、行业伙伴开展多场面对面洽谈。围绕产品海外注册准入、GMP 合规要求、质量标准共建、技术转移、新项目合作机会等议题进行深入沟通，充分了解不同国家药监法规最新动态，收集海外市场的实际需求与反馈，同时向海外合作伙伴介绍我司产品管线、生产体系、质量管控能力与国际化布局规划。
During the exhibition, our team held multiple face‑to‑face discussions with customers and industry partners from Europe, Central Asia, Southeast Asia, the Middle East and other regions. In‑depth communications covered topics including overseas product registration access, GMP compliance requirements, joint establishment of quality standards, technology transfer and potential new‑project cooperation. We gained full visibility into the latest regulatory updates from drug authorities across different countries and collected practical demands and feedback from overseas markets. Meanwhile, we presented our product pipeline, manufacturing systems, quality‑control capabilities and international development roadmap to overseas collaborators.
本次参会实现商务拓展与技术调研双向收获。一方面进一步夯实现有海外客户关系，挖掘潜在合作机会；另一方面，通过与全球同行的交流，学习行业前沿技术理念，对标国际先进质量与研发管理经验，为公司后续多国药品注册申报、产品海外商业化落地积累宝贵一手信息。
This participation delivered dual achievements in business development and technical research. On one hand, we further consolidated relationships with existing overseas customers and explored potential cooperation opportunities. On the other hand, exchanges with global peers enabled us to learn cutting‑edge industry concepts and benchmark against internationally‑advanced quality and R&D management practices. First‑hand insights obtained will support our subsequent multi‑country drug registration filings and the commercial roll‑out of our products in overseas markets.
面向未来，公司将持续坚定国际化发展战略，依托自身研发实力、完备的质量生产体系，持续推进海外市场布局，积极拓展全球医药合作网络，推动更多优质国产医药产品走向国际市场。
Moving forward, the Company will remain firmly committed to its internationalization strategy. Leveraging our in‑house R&D strengths and robust quality and manufacturing systems, we will continue expanding into overseas markets, proactively build up global pharmaceutical cooperation networks, and bring more high‑quality pharmaceutical products to the worldwide marketplace.
更多详细信息，请扫描下方二维码。
伍经理：17789750705（国内）
孙经理：18078993802（国内）
TEL：0898-66802207（国际）
E-mail：lizhongjing@zhonghe.cn（国际）
